ADJUVANT POST-SURGERY TREATMENT OF RECURRENT IDH2 MUTANT ANAPLASTIC OLIGODENTROGLIOMA (AO) WITH IDH2 INHIBITOR, ENASIDENIB: A CASE REPORT

被引：0
|
作者：
Kong, Xiao-Tang [1 ]
Fu, Beverly Dan [1 ]
Myung, Joon [1 ]
Bota, Daniela [2 ]
机构：
[1] UC Irvine, Orange, CA USA
[2] Univ Calif Irvine, Irvine, CA USA
来源：
NEURO-ONCOLOGY | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
INNV-07
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
    Ma, Rui
    Yun, Cai-Hong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 503 (04) : 2912 - 2917
  • [22] ENASIDENIB (AG-221), A SELECTIVE ORAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE 2 (IDH2) ENZYME, IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Stein, E. M.
    Fathi, A. T.
    DiNardo, C. D.
    Pollyea, D. A.
    Swords, R. T.
    Roboz, G. J.
    Collins, R.
    Sekeres, M. A.
    Stone, R. M.
    Attar, E. C.
    Tosolini, A.
    Xu, Q.
    Amatangelo, M.
    Gupta, I.
    Knight, R. D.
    De Botton, S.
    Tallman, M. S.
    Kantarjian, H. M.
    LEUKEMIA RESEARCH, 2017, 55 : S24 - S25
  • [23] Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation
    Geoerger, Birgit
    Schiff, Manuel
    Penard-Lacronique, Virginie
    Darin, Niklas
    Saad, Selim-Maria
    Duchon, Clarisse
    Lamaziere, Antonin
    Desmons, Aurore
    Pontoizeau, Clement
    Berlanga, Pablo
    Ducassou, Stephane
    Yen, Katharine
    Su, Michael
    Schenkein, David
    Ottolenghi, Chris
    De Botton, Stephane
    NATURE MEDICINE, 2023, 29 (06) : 1358 - +
  • [24] A new era after a long wait: Vorasetinib, an inhibitor of mutant IDH1 and IDH2 enzymes in patients with IDH-mutant glioma
    Silvani, Antonio
    Franceschi, Enrico
    TUMORI JOURNAL, 2024, 110 (03): : 160 - 161
  • [25] Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
    Atluri, Himachandana
    Maiti, Abhishek
    Sasaki, Koji
    Daver, Naval
    Alvarado, Yesid
    Hossain, Md Feroz
    Wang, Xuemei
    Pemmaraju, Naveen
    Takahashi, Koichi
    Borthakur, Gautam
    Ferrajoli, Alessandra
    Short, Nicholas
    Abbas, Hussein A.
    Ravandi, Farhad
    Jabbour, Elias
    Andreeff, Michael
    Garcia-Manero, Guillermo
    Kantarjian, Hagop
    Konopleva, Marina
    DiNardo, Courtney D.
    BLOOD, 2022, 140 : 6170 - 6172
  • [26] NOVEL TREATMENT OF TYPE II D-2-HYDROXYGLUTARIC ACIDURIA USING ENASIDENIB, AN IDH2 INHIBITIOR
    Gold, Jessica I.
    Stefanatos, Arianna K.
    Vanderver, Adeline
    Cuddapah, Sanmati
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (04) : 274 - 274
  • [27] Enasidenib treatment in two individuals with D-2-hydroxyglutaric aciduria carrying a germline IDH2 mutation
    Birgit Geoerger
    Manuel Schiff
    Virginie Penard-Lacronique
    Niklas Darin
    Selim-Maria Saad
    Clarisse Duchon
    Antonin Lamazière
    Aurore Desmons
    Clément Pontoizeau
    Pablo Berlanga
    Stéphane Ducassou
    Katharine Yen
    Michael Su
    David Schenkein
    Chris Ottolenghi
    Stéphane De Botton
    Nature Medicine, 2023, 29 : 1358 - 1363
  • [28] Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib: 2023 Update
    Atluri, Himachandana
    Mullin, Jillian
    Takahashi, Koichi
    Loghavi, Sanam
    Maiti, Abhishek
    Sasaki, Koji
    Daver, Naval
    Valero, Yesid Alvarado
    Pemmaraju, Naveen
    Borthakur, Gautam
    Hammond, Danielle E.
    Chien, Kelly S.
    Ferrajoli, Alessandra
    Short, Nicholas J.
    Abbas, Hussein A.
    Jabbour, Elias
    Andreeff, Michael
    Ravandi, Farhad
    Tidwell, Rebecca S. S.
    Wang, Xuemei
    Konopleva, Marina Y.
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    DiNardo, Courtney D.
    BLOOD, 2023, 142
  • [29] Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 (m IDH2) Acute Myeloid Leukemia (AML)
    Pollyea, Daniel A.
    Tallman, Martin S.
    De Botton, Stephane
    DiNardo, Courtney D.
    Kantarjian, Hagop M.
    Collins, Robert H.
    Stein, Anthony S.
    Xu, Qiang
    Tosolini, Alessandra
    Gupta, Ira
    Agresta, Samuel V.
    Stein, Eytan M.
    BLOOD, 2017, 130
  • [30] PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION
    Mellinghoff, Ingo
    Penas-Prado, Marta
    Peters, Katherine
    Cloughesy, Timothy
    Burris, Howard
    Maher, Elizabeth
    Janku, Filip
    Cote, Gregory
    De La Fuente, Macarena
    Clarke, Jennifer
    Steelman, Lori
    Le, Kha
    Xu, Huansheng
    Sonderfan, Alison
    Hummel, Diana
    Schoenfeld, Steven
    Yen, Katharine
    Pandya, Shuchi
    Wen, Patrick
    NEURO-ONCOLOGY, 2018, 20 : 18 - 18
12345